Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics
- 1 August 2013
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (16), 4511-4516
- https://doi.org/10.1016/j.bmcl.2013.06.054
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1Bioorganic & Medicinal Chemistry Letters, 2013
- Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human CancerCurrent Pharmaceutical Design, 2012
- Multiple Peaking Phenomena in Pharmacokinetic DispositionClinical Pharmacokinetics, 2010
- Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?Molecular Cancer Therapeutics, 2010
- Measuring and interpreting the selectivity of protein kinase inhibitorsJournal of Chemical Biology, 2009
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A reviewEuropean Journal Of Cancer, 2006
- Features of Selective Kinase InhibitorsChemistry & Biology, 2005
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction.Drug Metabolism and Disposition, 2002